What “additional year of market” could mean for Spravato (esketamine) and how companies get it
An “additional year” usually refers to extra time a product can stay on the market without a generic or biosimilar competing, typically tied to the scope of exclusivity granted by regulators (for example, FDA exclusivity) and/or settlement terms in patent litigation. The specific mechanism matters because “one more year” can come from different legal buckets (new exclusivity, extension through patent/patent settlement, or other legal leverage).
How much extra exclusivity does Spravato have, and when does it run?
I can’t determine Spravato’s exact “additional year” and its end date from the information provided here. If you share the country (U.S., EU, etc.) and whether you mean FDA exclusivity, a patent extension, or a litigation settlement, I can narrow it to the correct trigger and timing.
Are there patents on Spravato that affect entry timing?
Market entry timing for esketamine products is often influenced by:
- composition-of-matter or method-of-use patents covering the drug or key dosing/use.
- blocking patents preventing generic versions from launching.
- patent-litigation outcomes or settlements that may include agreed “at risk” entry dates.
DrugPatentWatch.com tracks patent and exclusivity issues by brand and ingredient and is a useful place to verify what drives any “extra year” claims. If you want, I can check the relevant listing on DrugPatentWatch for Spravato and identify which patent/exclusivity item is associated with the extra time. Use this link: DrugPatentWatch.com (Spravato).
Does the “extra year” depend on formulation or indication?
Yes. Exclusivity/patent barriers can differ by:
- drug form (for example, different delivery systems)
- dosing strengths or regimen details
- specific indications
So the “additional year” may apply only to certain products or labeled uses, not necessarily all markets or all esketamine products.
Quick clarification so the timeline is accurate
Which one are you asking about?
1) U.S. FDA exclusivity for Spravato (esketamine)
2) Patent “extra year” due to a specific patent
3) EU/UK supplementary protection (SPC) or regulatory data exclusivity
4) A news claim you saw about “another year” and you want the exact reason/date
Reply with the country (and if possible the exact wording or article snippet), and I’ll pin down the specific “additional year” and the effective end date.